Eloxx Pharmaceuticals, Inc.

ELOXOTCHealthcare● Active

$6.20

$-2.80(-31.11%)

Market Cap$46952426

P/E Ratio—

52W High$10

52W Low$0.00011

Avg Volume2K

Open$0.36

Beta-24.60

Overview

Eloxx Pharmaceuticals, Inc. (ELOX) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

ELOX · earnings · updated Jun 9, 2026

Latest Earnings

Q2 FY2026Report Date: May 5, 2026

EPS Actual

-$0.88

Est. -$6.40 · +86.3%

Revenue

—

Fiscal Period

Q2 FY2026

FY ends December

Report Date

May 5, 2026

After Market Close

▲ Beat EPS✓ 2-Quarter EPS Beat Streak

ELOX reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

—

Rev. $6.21B

Days Away84

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.—

Rev. Est.$6.21B

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
◌ Q3 FY2026	Aug 10, 2026	-$5.07	—	—	—	—	—
◌ Q3 FY2026	Aug 10, 2026	—	—	—	—	—	—
◌ Q2 FY2026	May 19, 2026	—	—	—	—	—	—
▲ Q2 FY2026	May 5, 2026	-$6.40	-$0.88	+86.3%	—	—	—
◌ Q1 FY2026	Feb 25, 2026	-$6.40	—	—	—	—	—
◌ Q2 FY2025	Apr 17, 2025	—	—	—	—	—	—
◌ Q1 FY2025	Mar 13, 2025	—	—	—	—	—	—
◌ Q1 FY2025	Feb 5, 2025	$1.54	—	—	—	—	—

Q3 FY2026

Aug 10, 2026

EPS Actual

—

EPS Est.

-$5.07

EPS Surpr.

—

Revenue

—

Q3 FY2026

Aug 10, 2026

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2026

May 19, 2026

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2026

May 5, 2026Beat

EPS Actual

-$0.88

EPS Est.

-$6.40

EPS Surpr.

+86.3%

Revenue

—

Q1 FY2026

Feb 25, 2026

EPS Actual

—

EPS Est.

-$6.40

EPS Surpr.

—

Revenue

—

Q2 FY2025

Apr 17, 2025

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2025

Mar 13, 2025

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2025

Feb 5, 2025

EPS Actual

—

EPS Est.

$1.54

EPS Surpr.

—

Revenue

—

Analyst Estimates

Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.

EPS Estimates

Period	Low	Consensus	High	# Analysts
Q3 FY2029	$-1.43	$-1.43	$-1.43	1
Q2 FY2029	$-1.97	$-1.97	$-1.97	1
Q1 FY2029	$-1.54	$-1.54	$-1.54	1
Q4 FY2028	$-1.97	$-1.97	$-1.97	1
Q3 FY2028	$-1.54	$-1.54	$-1.54	1
Q2 FY2028	$-2.55	$-2.55	$-2.55	1

Revenue Estimates

Period	Low	Consensus	High	# Analysts
Q3 FY2029	$0.0B	$0.0B	$0.0B	0
Q2 FY2029	$0.0B	$0.0B	$0.0B	0
Q1 FY2029	$0.0B	$0.0B	$0.0B	0
Q4 FY2028	$0.0B	$0.0B	$0.0B	1
Q3 FY2028	$0.0B	$0.0B	$0.0B	1
Q2 FY2028	$0.0B	$0.0B	$0.0B	1

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
▲ Q2 FY2026	May 5, 2026	+86.3%	$0.18	$0.13	-27.74%
▲ Q4 FY2023	Nov 13, 2023	+33.5%	$1.19	$1.18	-0.84%
▼ Q3 FY2023	Aug 14, 2023	-27.3%	$4.75	$5.73	+20.63%
▼ Q2 FY2023	May 15, 2023	-12.9%	$3.56	$10.90	+206.18%

Q2 FY2026-27.74%

Report Date

May 5, 2026

EPS Beat/Miss

+86.3%

Price Before

$0.18

Price After

$0.13

Q4 FY2023-0.84%

Report Date

Nov 13, 2023

EPS Beat/Miss

+33.5%

Price Before

$1.19

Price After

$1.18

Q3 FY2023+20.63%

Report Date

Aug 14, 2023

EPS Beat/Miss

-27.3%

Price Before

$4.75

Price After

$5.73

Q2 FY2023+206.18%

Report Date

May 15, 2023

EPS Beat/Miss

-12.9%

Price Before

$3.56

Price After

$10.90

Avg Beat Reaction-14.29%

Avg Miss Reaction+113.41%

Beat Rate2 / 4 quarters

Largest Move+206.18% (Q2 FY2023)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Eloxx Pharmaceuticals, Inc. (ELOX) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.88 — beating the analyst consensus of $-6.40 by +86.3%. ELOX has beaten EPS estimates for 2 consecutive quarters. The next ELOX earnings date is expected around September 1, 2026.

Each quarter, investors track ELOX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ELOX revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

ELOX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

ELOX earnings · 5 questions

Eloxx Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ELOX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ELOX historically reports after market close (AMC).

ELOX earnings datewhen is ELOX earningsELOX next earnings datewhen does ELOX report earningsELOX earnings calendar

▸ Source: FMP · Eloxx Pharmaceuticals, Inc. SEC filings · US GAAP · Eloxx Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026